214
Participants
Start Date
February 18, 2021
Primary Completion Date
June 20, 2025
Study Completion Date
June 30, 2025
Durvalumab
Durvalumab 1500 milligrams (mg) intravenous (IV) every 3 weeks + Cisplatin 75 mg/m² or Carboplatin AUC 5 IV every 3 weeks + Pemetrexed 500 mg/m² IV every 3 weeks for 4 to 6 cycles, followed by maintenance with Durvalumab 1500 mg IV every 4 weeks
Standard Chemotherapy
Cisplatin 75 mg/m² or Carboplatin AUC 5 IV every 3 weeks + Pemetrexed 500 mg/m² IV every 3 weeks) for 4 to 6 cycles, followed by Observation
Ipilimumab and Nivolumab
Ipilimumab 1 mg/kg every 6 weeks and Nivolumab 360 mg every 3 weeks or 3 mg/kg every 2 weeks for up to 2 years
Auckland City Hospital, Grafton
Chris O'Brien Lifehouse, Camperdown
Northern Cancer Institute (GenesisCare), Saint Leonards
Westmead Hospital, Westmead
Blacktown Hospital, Blacktown
Liverpool Hospital, Liverpool
Gosford Hospital, Gosford
Wyong Hospital, Hamlyn Terrace
Calvary Mater Newcastle, Waratah
Coffs Harbour Health Campus, Coffs Harbour
Canberra Hospital, Garran
Nepean Hospital, Kingswood
Orange Health Service, Orange
Peter MacCallum Cancer Centre, Melbourne
Sunshine Hospital (Western Health), Saint Albans
Austin Hospital, Heidelberg
Epworth HealthCare - Richmond, Richmond
Monash Health, Clayton
Peninsula & South Eastern Haematology and Oncology Group, Frankston
Goulburn Valley Health, Shepparton
Icon Cancer Care Chermside, Chermside
The Prince Charles Hospital, Chermside
Icon Cancer Care Wesley, Auchenflower
Icon Cancer Care South Brisbane, South Brisbane
Princess Alexandra Hospital, Woolloongabba
Sunshine Coast University Hospital, Birtinya
Townsville University Hospital, Douglas
The Queen Elizabeth Hospital, Woodville South
Flinders Medical Centre, Bedford Park
Sir Charles Gairdner Hospital (SCGH), Nedlands
Royal Hobart Hospital, Hobart
Launceston General Hospital, Launceston
Memorial Sloan Kettering, New York
Allegheny Cancer Center, Pittsburgh
Penn State Cancer Institute, Hershey
Moffitt Cancer Center, Tampa
Abramson Cancer Cener at Penn Presbyterian Medical Center, Philadelphia
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore
University of Virginia, Charlottesville
Emory University, Atlanta
University of Miami, Miami
The Ohio State University, Columbus
Cleveland Clinic Foundation, Cleveland
University of Cincinnati, Cincinnati
University of Michigan, Ann Arbor
Metro Minnesota Community Oncology Research Consortium, Saint Louis Park
NorthShore University Health System/Kellogg Cancer Center, Evanston
University of Chicago, Chicago
University of Texas Southwestern Medical Center, Dallas
Baylor College of Medicine, Houston
MD Anderson Cancer Center, Houston
University of California San Diego, La Jolla
Massaschusetts General Hospital, Boston
Dana Farber Cancer Institute, Boston
Morristown Medical/Atlantic Health, Morristown
Jersey Shore University Medical Center, Neptune City
Rutgers Cancer Institute of New Jersey, New Brunswick
Collaborators (1)
AstraZeneca
INDUSTRY
Thoracic Oncology Group Australasia (TOGA)
UNKNOWN
University of Sydney
OTHER
PrECOG, LLC.
OTHER